Purely Proteins Ltd (Cambridge, UK) announced today its Board’s decision to accelerate the Company’s internal program to discover and develop proprietary purification processes to selectively purify human serum therapeutics. Together with its existing partnered programs, this new initiative will position the company to offer proprietary products in addition to value-creating services. Initial targets in the Purely Proteins program include the major serum proteins Immunoglobulin G and Alpha-1 Antitrypsin, in addition to specific human growth factors and infectious agents. In the latter category, specific focus will be on viruses and prion proteins that pose major health threats and offer significant market opportunities for innovative products. The market for human Alpha-1 Antitrypsin alone is projected to grow to $1 billion by 2010, while IgG therapeutics already represent a significant proportion of today’s $26 billion biotherapeutic market.
Commenting on this announcement, Purely Proteins’ Chief Executive Officer, Dr. David Bailey, said, “This is a significant development for Purely Proteins as we move from being a service company into a product-based discovery company. Our integrated ligand discovery platform allows the parallel development of affinity ligands for many proteins simultaneously, permitting rapid optimisation of purification processes. We have selected a core set of high- value therapeutic targets for this program, which will be partnered prior to commercialisation. This will allow PP to capture more value from its technology platform without significantly increasing the risk for its investors.”
Purely Proteins has been established to exploit the increasing need for and use of human proteins in human medical research. The company purifies suites of human proteins, as both drug targets and bio-therapeutics, using proprietary processes that ensure both high purity and biological activity. Purely Proteins also offers ligand screening services, backed by state-of-the-art informatics, to examine therapeutic targeting to these proteins.